During the past decade, Karma Clinical Trials conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 3 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 2 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Karma Clinical Trials" are "Psoriasis" (2 trials), "Plaque Psoriasis" (1 trials), "Psoriatic Arthritis" (1 trials) and "Skin Diseases" (1 trials). Many other conditions were trialed in "Karma Clinical Trials" in a lesser frequency.

Most popular intervention types in "Karma Clinical Trials" are "Drug" (4 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Apremilast" (1 trials), "Apremilast (CC-10004)" (1 trials), "Apremilast 30 mg" (1 trials) and "JTE-051" (1 trials). Other intervention names were less common.

The vast majority of trials in "Karma Clinical Trials" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Karma Clinical Trials". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Karma Clinical Trials, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Karma Clinical Trials, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".